GlaxoSmithKline Vaccines Pty Ltd; Melbourne, VIC Australia.
Hum Vaccin Immunother. 2013 Aug;9(8):1617-25. doi: 10.4161/hv.24831. Epub 2013 Jun 3.
This study was conducted to assess the impact of administration of two-dose rotavirus (RV) vaccine (RIX4414; GlaxoSmithKline Vaccines) among children aged less than 5 y in three states/territories of Australia. Aggregated and de-identified data on rotavirus gastroenteritis (RVGE) and all-cause gastroenteritis (AGE) from July 1998-June 2009 were obtained from the Australian Institute of Health and Welfare database. The baseline incidence (July 1998-June 2006) of RVGE hospitalizations before RV vaccine introduction in New South Wales (NSW), the Australian Capital Territory (ACT) and the Northern Territory (NT) were 33.75, 42.93 and 288.67 per 10,000 child-years, respectively among children aged 0-11 mo. Following RV vaccine introduction in NSW, the ACT and the NT, incidence of RVGE hospitalizations reduced to 13.06, 17.35 and 47.52 per 10,000 child-years, respectively, during July 2007-June 2008 and 3.87, 8.40 and 122.79 per 10,000 child-years, respectively, during July 2008-June 2009 among children aged 0-11 mo. Reductions in RVGE and AGE were also observed in all children below 5 y of age in NSW and the ACT. Overall reduction in hospitalizations due to RVGE and AGE was observed following RV vaccine introduction into the NIP in Australia.
本研究旨在评估在澳大利亚三个州/地区为年龄小于 5 岁的儿童接种两剂轮状病毒（RV）疫苗（RIX4414；葛兰素史克疫苗）的效果。从澳大利亚卫生福利研究所数据库中获取了 1998 年 7 月至 2009 年 6 月期间轮状病毒胃肠炎（RVGE）和所有病因胃肠炎（AGE）的汇总和去识别数据。在新南威尔士州（NSW）、澳大利亚首都领地（ACT）和北领地（NT）引入 RV 疫苗之前，2006 年 7 月至 6 月，0-11 月龄儿童 RVGE 住院的基线发病率（1998 年 7 月至 2006 年 6 月）分别为每 10000 名儿童 33.75、42.93 和 288.67。在 NSW、ACT 和 NT 引入 RV 疫苗后，2007 年 7 月至 2008 年 6 月期间，0-11 月龄儿童 RVGE 住院的发病率分别降至每 10000 名儿童 13.06、17.35 和 47.52，2008 年 7 月至 2009 年 6 月期间分别降至每 10000 名儿童 3.87、8.40 和 122.79，0-11 月龄儿童。在 NSW 和 ACT，所有年龄小于 5 岁的儿童中也观察到 RVGE 和 AGE 的减少。在澳大利亚国家免疫计划（NIP）中引入 RV 疫苗后，观察到 RVGE 和 AGE 导致的住院人数总体减少。
